Concretely: a 30G needle · 5 mg/mL.
Please show the division. I want to check my own against yours.
I would like the general form as well as the specific number, so I can apply it again.
How many significant figures are actually justified here?
At 5 mg/mL every microlitre left behind is 5 µg, so a 50 µL hub costs 0.25 mg per draw and a 5 µL fixed-needle barrel costs 0.025 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 2.5 mg gone, which at 5 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 12.5 per cent; against a 0.25 mg dose it is 100 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 30G needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
The relevant detail is that a fixed-needle insulin syringe holds roughly 3 to 5 µL dead space and costs the same as a luer-lock syringe with 35 to 100 µL dead space.
Draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.
Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
The switch nearly doubles your vial, which is better than most other optimisations combined.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemSpecifically, this is arithmetic, so let us do the arithmetic and see where the losses actually are.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
If cost matters, this is the first thing to change, not the last.
In practice, dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.
The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
Configuration A — 1 mL luer-lock plus detachable needle, dead space 84 µL: each draw removes 100 + 84 = 184 µL. Draws available from 2,000 µL = 2000 / 184 = 10.87, so 10 full draws.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
Put another way, the distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.
The relevant detail is that dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.
Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.
The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.
The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.